<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334866</url>
  </required_header>
  <id_info>
    <org_study_id>D03782</org_study_id>
    <nct_id>NCT01334866</nct_id>
  </id_info>
  <brief_title>Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery</brief_title>
  <acronym>MICS</acronym>
  <official_title>Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study has been developed to evaluate the clinical outcomes in patients
      undergoing coronary artery bypass grafting via Minimally Invasive Coronary Surgery (MICS); a
      minimally invasive coronary bypass procedure that is done on a beating heart via a smaller
      chest incision, thus avoiding the invasiveness of the standard procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical Success (Graft Patency) in a MICS Approach</measure>
    <time_frame>At time of procedure (day 1)</time_frame>
    <description>For each subject, the endpoint for technical success (graft patency) in a MICS approach is defined as acceptable flow for graft size for an anastamosis. This will be characterized by the surgeon's assessment/angiography after the graft is complete.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural Success in a MICS Approach</measure>
    <time_frame>At time of procedure (day 1)</time_frame>
    <description>A successful procedure can be defined as a procedures not requiring conversion (sternotomy). This will be characterized by whether the graft procedure can be completed through the minimally invasive thoracotomy without having to convert to a sternotomy in order to complete the grafting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patency of the Index Graft at 6 Months</measure>
    <time_frame>6 months post-procedure</time_frame>
    <description>For each subject, the endpoint is the percent of stenosis collected on the subject's 6 month angiography form. This will be characterized for each graft using the FitzGibbon scoring system based on the 64-Slice CT Angiography results.
The FitzGibbon Scoring system is as follows:
A:Excellent graft with unimpaired runoff (&lt; 50% stenosis) B:Stenosis reducing caliber of proximal or distal anastomoses or trunk to &lt;50% of the grafted coronary artery.
O:Occluded (100% stenosed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite Major Adverse Event Rate (Early)</measure>
    <time_frame>During procedure (day 1) and within 30 days post-procedure or hospital discharge, whichever is longer (throughout 6 month evaluation)</time_frame>
    <description>During procedure and within 30 days post-procedure or hospital discharge, whichever is longer. The adverse events will include:
Major hemorrhage/bleeding requiring surgical intervention
Aortic complications
Graft vessel revision (GVR)
Transient ischemic attacks (TIA)
Cerebrovascular accidents (CVA)/stroke
Myocardial infarction (MI)
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Major Adverse Event Rate (Late)</measure>
    <time_frame>After 30 days post-procedure or hospital discharge, whichever is longer through the 6-Month evaluation</time_frame>
    <description>Characterize the composite major adverse event rate after 30 days post-procedure or hospital discharge, whichever is longer through the 6-Month evaluation. The major adverse events will include:
Major hemorrhage/bleeding requiring surgical intervention
Aortic complications
Graft vessel revision (GVR)
Transient ischemic attacks (TIA)
Cerebrovascular accidents (CVA)/stroke
Myocardial infarction (MI)
Death</description>
  </secondary_outcome>
  <enrollment type="Actual">91</enrollment>
  <condition>Arteriosclerosis of Coronary Artery Bypass Graft</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally invasive coronary artery bypass graft surgery</intervention_name>
    <description>The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.</description>
    <other_name>MICS CABG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; or equal to 18 and &lt; or equal to 80 years of age

          -  Suitable minimally invasive coronary surgery (MICS) candidate for non-emergent first
             time, single or multivessel coronary artery bypass grafting (on pump or off pump)

          -  Left ventricle ejection fraction &gt;30%

          -  Willing and able to provide written informed consent and comply with study
             requirements

        Exclusion Criteria:

          -  Severe cerebrovascular disease within 90 days of surgery including history of prior
             stroke.

          -  Previous cardiac surgery procedures such as CABG revisions, surgical ablations or
             valve replacements

          -  Congestive heart failure with a New York Heart Association (NYHA) Class IV

          -  History of renal insufficiency (i.e. prior serum creatinine of &gt;2mg/dl) and/or
             requiring dialysis

          -  Uncontrolled diabetes (i.e. &gt;2 serum glucose concentrations of &gt;350 mg/dl)

          -  Severe uncontrolled systemic hypertension (i.e. systolic pressure &gt;160 mmHg)

          -  Peripheral/systemic active infection excluding the patient from cardiac surgery

          -  Life expectancy of less than 1 year due to other illness such as cancer or pulmonary,
             hepatic or renal disease

          -  Participation in another investigational protocol that may confound the results of
             this study

          -  Female of child bearing potential and lactating or intends to become pregnant during
             the study

          -  Severe distal disease and small posterior lateral targets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph McGinn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staten Island University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.medtronic.com/</url>
    <description>Medtronic, Inc. Corporate Website</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <results_first_submitted>August 9, 2013</results_first_submitted>
  <results_first_submitted_qc>November 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2013</results_first_posted>
  <last_update_submitted>November 3, 2013</last_update_submitted>
  <last_update_submitted_qc>November 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minimally invasive coronary surgery</keyword>
  <keyword>Coronary artery bypass grafting</keyword>
  <keyword>MICS CABG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 91 subjects were enrolled, with 89 subjects receiving the study treatment. The first subject was enrolled on December 30, 2009 and the last subject was enrolled on October 4, 2012. Of the 89 subjects treated with the study procedure, 72 subjects completed the 6 month follow-up primary endpoint visit.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Minimally Invasive Coronary Artery Bypass Grafting</title>
          <description>91 subjects were enrolled, with 89 subjects receving the study treatment. Of the 89 subjects treated with the study procedure, 72 subjects completed the 6 month follow-up primary endpoint visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91">91 subjects were enrolled in the study; with 89 subjects receiving the study treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>medically necessary prior to procedure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>medically necessary post-procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Completion Cohort</title>
          <description>91 subjects were enrolled, with 89 subjects receving the study treatment. Of the 89 subjects treated with the study procedure, 72 subjects completed the 6 month follow-up primary endpoint visit.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Technical Success (Graft Patency) in a MICS Approach</title>
        <description>For each subject, the endpoint for technical success (graft patency) in a MICS approach is defined as acceptable flow for graft size for an anastamosis. This will be characterized by the surgeon's assessment/angiography after the graft is complete.</description>
        <time_frame>At time of procedure (day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Coronary Artery Bypass Grafting</title>
            <description>89 Subjects received study treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success (Graft Patency) in a MICS Approach</title>
          <description>For each subject, the endpoint for technical success (graft patency) in a MICS approach is defined as acceptable flow for graft size for an anastamosis. This will be characterized by the surgeon's assessment/angiography after the graft is complete.</description>
          <units>percentage of grafts</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Grafts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Procedural Success in a MICS Approach</title>
        <description>A successful procedure can be defined as a procedures not requiring conversion (sternotomy). This will be characterized by whether the graft procedure can be completed through the minimally invasive thoracotomy without having to convert to a sternotomy in order to complete the grafting.</description>
        <time_frame>At time of procedure (day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Procedure Cohort</title>
            <description>89 Subjects received study treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success in a MICS Approach</title>
          <description>A successful procedure can be defined as a procedures not requiring conversion (sternotomy). This will be characterized by whether the graft procedure can be completed through the minimally invasive thoracotomy without having to convert to a sternotomy in order to complete the grafting.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patency of the Index Graft at 6 Months</title>
        <description>For each subject, the endpoint is the percent of stenosis collected on the subject's 6 month angiography form. This will be characterized for each graft using the FitzGibbon scoring system based on the 64-Slice CT Angiography results.
The FitzGibbon Scoring system is as follows:
A:Excellent graft with unimpaired runoff (&lt; 50% stenosis) B:Stenosis reducing caliber of proximal or distal anastomoses or trunk to &lt;50% of the grafted coronary artery.
O:Occluded (100% stenosed)</description>
        <time_frame>6 months post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Coronary Artery Bypass Grafting</title>
            <description>91 subjects were enrolled, with 89 subjects receving the study treatment. Of the 89 subjects treated with the study procedure, 72 subjects completed the 6 month follow-up primary endpoint visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Patency of the Index Graft at 6 Months</title>
          <description>For each subject, the endpoint is the percent of stenosis collected on the subject's 6 month angiography form. This will be characterized for each graft using the FitzGibbon scoring system based on the 64-Slice CT Angiography results.
The FitzGibbon Scoring system is as follows:
A:Excellent graft with unimpaired runoff (&lt; 50% stenosis) B:Stenosis reducing caliber of proximal or distal anastomoses or trunk to &lt;50% of the grafted coronary artery.
O:Occluded (100% stenosed)</description>
          <units>percentage of grafts</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Grafts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade O</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite Major Adverse Event Rate (Early)</title>
        <description>During procedure and within 30 days post-procedure or hospital discharge, whichever is longer. The adverse events will include:
Major hemorrhage/bleeding requiring surgical intervention
Aortic complications
Graft vessel revision (GVR)
Transient ischemic attacks (TIA)
Cerebrovascular accidents (CVA)/stroke
Myocardial infarction (MI)
Death</description>
        <time_frame>During procedure (day 1) and within 30 days post-procedure or hospital discharge, whichever is longer (throughout 6 month evaluation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Coronary Artery Bypass Grafting</title>
            <description>89 Subjects received study treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Major Adverse Event Rate (Early)</title>
          <description>During procedure and within 30 days post-procedure or hospital discharge, whichever is longer. The adverse events will include:
Major hemorrhage/bleeding requiring surgical intervention
Aortic complications
Graft vessel revision (GVR)
Transient ischemic attacks (TIA)
Cerebrovascular accidents (CVA)/stroke
Myocardial infarction (MI)
Death</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Major Adverse Event Rate (Late)</title>
        <description>Characterize the composite major adverse event rate after 30 days post-procedure or hospital discharge, whichever is longer through the 6-Month evaluation. The major adverse events will include:
Major hemorrhage/bleeding requiring surgical intervention
Aortic complications
Graft vessel revision (GVR)
Transient ischemic attacks (TIA)
Cerebrovascular accidents (CVA)/stroke
Myocardial infarction (MI)
Death</description>
        <time_frame>After 30 days post-procedure or hospital discharge, whichever is longer through the 6-Month evaluation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Coronary Artery Bypass Grafting</title>
            <description>89 Subjects received study treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Major Adverse Event Rate (Late)</title>
          <description>Characterize the composite major adverse event rate after 30 days post-procedure or hospital discharge, whichever is longer through the 6-Month evaluation. The major adverse events will include:
Major hemorrhage/bleeding requiring surgical intervention
Aortic complications
Graft vessel revision (GVR)
Transient ischemic attacks (TIA)
Cerebrovascular accidents (CVA)/stroke
Myocardial infarction (MI)
Death</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events reported from treatment through 6-month follow-up.</time_frame>
      <desc>Adverse events were classified as serious by the PI following ISO 14155 standards.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Procedure Cohort</title>
          <description>89 Subjects received study treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia and blood loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Bleeding (2), Bleeding/Oozing (1)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Low Cardiac Index</sub_title>
                <description>Low cardiac index (2), low cardiac index and central venous pressure (1)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical Blood Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Subcutaneous Emphysema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Atelectasis and Pleural Effusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristin Lawman</name_or_title>
      <organization>Medtronic, Inc.</organization>
      <phone>763-514-9809</phone>
      <email>kristin.j.lawman@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

